<?xml version="1.0" encoding="UTF-8"?>
<p id="p0060">CyPA is a potential drug target for coronaviruses [
 <xref rid="bb0170" ref-type="bibr">33</xref>]. Brunn's team at LMU University in Germany reported that the N protein of SARS-CoV binds closely to CyPA in humans, and that inhibiting the binding of two proteins by CsA inhibits the replication of hCoV-229E [
 <xref rid="bb0020" ref-type="bibr">4</xref>,
 <xref rid="bb0180" ref-type="bibr">35</xref>,
 <xref rid="bb0185" ref-type="bibr">36</xref>]. In 2011, it was reported that CsA inhibits CoV infection [
 <xref rid="bb0165" ref-type="bibr">32</xref>]. In the same year, the Brunn team demonstrated that the host's Cyps were a possible target for CoV, and also noted that non-immunosuppressive cyclosporine derivatives may have the potential to become a panCoV inhibitor [
 <xref rid="bb0170" ref-type="bibr">33</xref>]. Later, in 2014, the Brunn team further confirmed that the low-host CyPA could prevent the replication of hCoV-NL63. In a recent study, Alisporivir, which is a non-immunosuppressive CyPA inhibitor, was reported to reduce SARS-CoV-2 RNA production 
 <italic>in vitro</italic> with an EC50 of 0.46 ± 0.04 μM and Alisporivir inhibited a post-entry step in the life cycle of SARS-CoV-2 [
 <xref rid="bb0235" ref-type="bibr">45</xref>].
</p>
